CN106661579B - 用于预防器官中缺血再灌注损伤的方法和组合物 - Google Patents

用于预防器官中缺血再灌注损伤的方法和组合物 Download PDF

Info

Publication number
CN106661579B
CN106661579B CN201580041391.4A CN201580041391A CN106661579B CN 106661579 B CN106661579 B CN 106661579B CN 201580041391 A CN201580041391 A CN 201580041391A CN 106661579 B CN106661579 B CN 106661579B
Authority
CN
China
Prior art keywords
kidney
donor
dialysis
inhibitor
iri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580041391.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106661579A (zh
Inventor
E·C·斯夸尔斯
S·埃尔利赫
D·罗森斯坦
N·莎伦
D·J·奥登海默
E·范斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Priority to CN202011264844.9A priority Critical patent/CN112410336A/zh
Publication of CN106661579A publication Critical patent/CN106661579A/zh
Application granted granted Critical
Publication of CN106661579B publication Critical patent/CN106661579B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580041391.4A 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物 Expired - Fee Related CN106661579B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011264844.9A CN112410336A (zh) 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29
US62/004,239 2014-05-29
PCT/US2015/032499 WO2015183842A1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011264844.9A Division CN112410336A (zh) 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物

Publications (2)

Publication Number Publication Date
CN106661579A CN106661579A (zh) 2017-05-10
CN106661579B true CN106661579B (zh) 2020-12-04

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011264844.9A Pending CN112410336A (zh) 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物
CN201580041391.4A Expired - Fee Related CN106661579B (zh) 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202011264844.9A Pending CN112410336A (zh) 2014-05-29 2015-05-27 用于预防器官中缺血再灌注损伤的方法和组合物

Country Status (18)

Country Link
US (3) US20170081665A1 (enExample)
EP (2) EP3444349B1 (enExample)
JP (2) JP2017521374A (enExample)
KR (1) KR20170007492A (enExample)
CN (2) CN112410336A (enExample)
AU (1) AU2015267160B2 (enExample)
BR (1) BR112016028009A2 (enExample)
CA (1) CA2949109A1 (enExample)
DK (2) DK3444349T3 (enExample)
ES (2) ES2683869T3 (enExample)
HU (2) HUE040092T2 (enExample)
IL (2) IL248912A0 (enExample)
LT (2) LT3444349T (enExample)
MX (2) MX373950B (enExample)
PL (2) PL3149172T3 (enExample)
PT (2) PT3444349T (enExample)
SI (2) SI3444349T1 (enExample)
WO (1) WO2015183842A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3737388A4 (en) * 2018-01-12 2021-10-06 University of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
GB202016863D0 (en) * 2020-10-23 2020-12-09 Causeway Therapeutics Ltd Microrna-29 compounds, compositions and uses in therapy
CN118354797A (zh) * 2021-12-22 2024-07-16 株式会社Na疫苗研究所 用于预防或治疗缺血-再灌注损伤的组合物以及其用途
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 一种qpi-1002的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101815521A (zh) * 2007-10-03 2010-08-25 夸克医药公司 新siRNA结构
CN102458418A (zh) * 2009-06-08 2012-05-16 夸克医药公司 治疗慢性肾病的方法
CN102643818A (zh) * 2004-09-28 2012-08-22 夸克医药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
WO2014043292A1 (en) * 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
AU3584200A (en) 1999-01-29 2000-08-18 Board Of Trustees Of The University Of Illinois, The P53 inhibitors and therapeutic use of the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
WO2005111238A2 (en) 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
WO2007091269A2 (en) 2006-02-08 2007-08-16 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
DK2170403T3 (da) 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
US8722638B2 (en) * 2008-06-20 2014-05-13 Children's Medical Center Corporation Methods for the modulation of angiogenesis
EP2504435B1 (en) 2009-11-26 2019-11-13 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
JPWO2011138966A1 (ja) 2010-05-06 2013-07-22 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
WO2012068381A2 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102643818A (zh) * 2004-09-28 2012-08-22 夸克医药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
CN101815521A (zh) * 2007-10-03 2010-08-25 夸克医药公司 新siRNA结构
CN102458418A (zh) * 2009-06-08 2012-05-16 夸克医药公司 治疗慢性肾病的方法
WO2014043292A1 (en) * 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
p53对缺血再灌注损伤后肾小管上皮细胞演变的影响;李开龙 等;《细胞与分子免疫学杂志》;20070131;第23卷(第1期);第10页左栏第3段 *

Also Published As

Publication number Publication date
PL3149172T3 (pl) 2018-10-31
LT3444349T (lt) 2021-04-12
US20180305696A1 (en) 2018-10-25
CA2949109A1 (en) 2015-12-03
DK3149172T3 (en) 2018-08-20
JP2020128383A (ja) 2020-08-27
CN112410336A (zh) 2021-02-26
KR20170007492A (ko) 2017-01-18
MX2020005794A (es) 2020-10-28
MX2016015635A (es) 2017-04-25
AU2015267160A1 (en) 2016-12-01
PL3444349T3 (pl) 2021-06-28
PT3149172T (pt) 2018-10-08
EP3444349A1 (en) 2019-02-20
DK3444349T3 (da) 2021-04-12
PT3444349T (pt) 2021-04-06
EP3444349B1 (en) 2021-01-06
CN106661579A (zh) 2017-05-10
IL248912A0 (en) 2017-01-31
LT3149172T (lt) 2018-09-10
ES2683869T3 (es) 2018-09-28
SI3149172T1 (sl) 2018-10-30
AU2015267160A8 (en) 2016-12-08
MX373950B (es) 2020-07-13
US20170081665A1 (en) 2017-03-23
HUE040092T2 (hu) 2019-02-28
US9868953B2 (en) 2018-01-16
ES2862185T3 (es) 2021-10-07
US20170335327A1 (en) 2017-11-23
IL278144B (en) 2021-07-29
EP3149172A1 (en) 2017-04-05
WO2015183842A1 (en) 2015-12-03
JP2017521374A (ja) 2017-08-03
EP3149172B1 (en) 2018-07-18
IL278144A (en) 2020-11-30
HUE054226T2 (hu) 2021-08-30
AU2015267160B2 (en) 2021-07-29
SI3444349T1 (sl) 2021-07-30
BR112016028009A2 (pt) 2018-02-20

Similar Documents

Publication Publication Date Title
CN106661579B (zh) 用于预防器官中缺血再灌注损伤的方法和组合物
US12364707B2 (en) Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
US11911484B2 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA2753388C (en) Endo180 antibody to treat cancer and fibrotic disease
JP6628787B2 (ja) 拮抗性抗ｏｘ４０ｌ抗体およびそれらの使用方法
US12496352B2 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3195275A1 (en) In vivo targeting of t cells for mrna therapeutics
JP2020500157A (ja) Ｃ３阻害のための組み合わせ治療
JP2023514570A (ja) 補体阻害のためのｒｎａ
WO2009021295A2 (en) Inhibition of alpha synuclein toxicity
US20250235549A1 (en) Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof
WO2017147408A1 (en) Methods for the treatment of hematologic cancer
TW202430635A (zh) 用於抑制補體成分C3(C3)表現之RNAi藥劑、其醫藥組合物及使用方法
OA21722A (en) Compositions and methods for inhibiting expression of Prekallikrein (PKK) protein.
TW202309279A (zh) 用於補體抑制之ｒｎａ
HK40014102A (en) Combination therapy for c3 inhibition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201204

CF01 Termination of patent right due to non-payment of annual fee